User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.

  • Open access
  • PDF
  • 939.22 K
  • Open access
  • PDF
  • 945.43 K
  1. Kim W. R., Lake J. R., Smith J. M., Schladt D. P., Skeans M. A., Harper A. M., Wainright J. L., Snyder J. J., Israni A. K., Kasiske B. L., OPTN/SRTR 2016 Annual Data Report: Liver, 10.1111/ajt.14559
  2. Hart A., Smith J. M., Skeans M. A., Gustafson S. K., Wilk A. R., Robinson A., Wainright J. L., Haynes C. R., Snyder J. J., Kasiske B. L., Israni A. K., OPTN/SRTR 2016 Annual Data Report: Kidney, 10.1111/ajt.14557
  3. Astellas Pharma Europe Ltd.Prograf 0.5 mg 1 mg 5 mg hard capsules summary of product characteristics.https://www.medicines.org.uk/emc/product/6720. Accessed April 17 2019.
  4. US Food and Drug Administration.Astagraf XL prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204096s005lbl.pdf. Accessed February 14 2019.
  5. Astellas Pharma Europe Ltd.Advagraf 0.5 mg 1 mg 3 mg and 5 mg prolonged‐release hard capsules summary of product characteristics.https://www.medicines.org.uk/emc/product/345/smpc. Accessed February 20 2019.
  6. Butler Janet A., Roderick Paul, Mullee Mark, Mason Juan C., Peveler Robert C., Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review : , 10.1097/01.tp.0000110408.83054.88
  7. Shemesh Eyal, Duncan Sarah, Anand Ravinder, Shneider Benjamin L., Alonso Estella M., Mazariegos George V., Venick Robert S., Annunziato Rachel A., Bucuvalas John C., Trajectory of adherence behavior in pediatric and adolescent liver transplant recipients: The medication adherence in children who had a liver transplant cohort : Shemesh et al., 10.1002/lt.24837
  8. Chisholm-Burns M. A., Spivey C. A., Rehfeld R., Zawaideh M., Roe D. J., Gruessner R., Immunosuppressant Therapy Adherence and Graft Failure Among Pediatric Renal Transplant Recipients, 10.1111/j.1600-6143.2009.02793.x
  9. Borra L. C. P., Roodnat J. I., Kal J. A., Mathot R. A. A., Weimar W., van Gelder T., High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation, 10.1093/ndt/gfq096
  10. Beckebaum Susanne, Iacob Speranta, Sweid Dani, Sotiropoulos Georgios C., Saner Fuat, Kaiser Gernot, Radtke Arnold, Klein Christian G., Erim Yesim, de Geest Sabina, Paul Andreas, Gerken Guido, Cicinnati Vito R., Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation : Conversion of LT patients to once-daily tacrolimus formulation, 10.1111/j.1432-2277.2011.01254.x
  11. Eberlin M., Otto G., Krämer I., Increased Medication Compliance of Liver Transplant Patients Switched From a Twice-Daily to a Once-Daily Tacrolimus-Based Immunosuppressive Regimen, 10.1016/j.transproceed.2012.10.037
  12. Kuypers Dirk R.J., Peeters Patrick C., Sennesael Jacques J., Kianda Mireille N., Vrijens Bernard, Kristanto Paulus, Dobbels Fabienne, Vanrenterghem Yves, Kanaan Nada, Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients : A Randomized Controlled Trial Using Electronic Monitoring, 10.1097/tp.0b013e3182725532
  13. Kurnatowska I., Krawczyk J., Oleksik T., Nowicki M., Tacrolimus Dose and Blood Concentration Variability in Kidney Transplant Recipients Undergoing Conversion From Twice Daily to Once Daily Modified Release Tacrolimus, 10.1016/j.transproceed.2011.08.021
  14. Alloway R., Steinberg S., Khalil K., Gourishankar S., Miller J., Norman D., Hariharan S., Pirsch J., Matas A., Zaltzman J., Wisemandle K., Fitzsimmons W., First M.R., Conversion of Stable Kidney Transplant Recipients From a Twice Daily Prograf-Based Regimen to a Once Daily Modified Release Tacrolimus-Based Regimen, 10.1016/j.transproceed.2004.12.222
  15. Florman S., Alloway R., Kalayoglu M., Lake K., Bak T., Klein A., Klintmalm G., Busque S., Brandenhagen D., Lake J., Wisemandle K., Fitzsimmons W., First M.R., Conversion of Stable Liver Transplant Recipients From a Twice-Daily Prograf-Based Regimen to a Once-Daily Modified Release Tacrolimus-Based Regimen, 10.1016/j.transproceed.2004.11.086
  16. Heffron T. G., Pescovitz M. D., Florman S., Kalayoglu M., Emre S., Smallwood G., Wisemandle K., Anania C., Dhadda S., Sawamoto T., Keirns J., Fitzsimmons W., First M. R., Once-Daily Tacrolimus Extended-Release Formulation: 1-Year Post-Conversion in Stable Pediatric Liver Transplant Recipients, 10.1111/j.1600-6143.2007.01803.x
  17. Quintero Jesús, Juampérez Javier, Ortega Juan, Molino José A., Castells Lluis, Bilbao Itxarone, Rodrigo Carlos, Charco Ramón, Conversion from twice-daily to once-daily tacrolimus formulation in pediatric liver transplant recipients - a long-term prospective study, 10.1111/tri.13037
  18. Carcas‐Sansuán AJ, Liver Transplant, 19, 1151 (2013)
  19. Pape Lars, Heidotting Nele, Ahlenstiel Thurid, Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients, 10.4061/2011/126251
  20. Min S. I., Ha J., Kang H. G., Ahn S., Park T., Park D. D., Kim S. M., Hong H. J., Min S. K., Ha I. S., Kim S. J., Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy : Once-Daily Tacrolimus in Pediatric Patients, 10.1111/ajt.12274
  21. Carcas-Sansuán Antonio J., Espinosa-Román Laura, Almeida-Paulo Gonzalo N., Alonso-Melgar Angel, García-Meseguer Carmen, Fernández-Camblor Carlota, Medrano Nicolás, Ramirez Elena, Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up, 10.1007/s00467-013-2564-y
  22. Rubik Jacek, Debray Dominique, Iserin Franck, Vondrak Karel, Sellier‐Leclerc Anne‐Laure, Kelly Deirdre, Czubkowski Piotr, Webb Nicholas J. A., Riva Silvia, D'Antiga Lorenzo, Marks Stephen D., Rivet Christine, Tönshoff Burkhard, Kazeem Gbenga, Undre Nasrullah, Comparative pharmacokinetics of tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus to prolonged‐release tacrolimus formulation, 10.1111/petr.13391
  23. Schwartz GJ, Pediatrics, 58, 259 (1976)
  24. US National Institutes of Health.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published 2010. Accessed April 17 2019.
  25. Sellarés J., de Freitas D. G., Mengel M., Reeve J., Einecke G., Sis B., Hidalgo L. G., Famulski K., Matas A., Halloran P. F., Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence : Attributing Causes of Kidney Transplant Loss, 10.1111/j.1600-6143.2011.03840.x
  26. Wiebe C., Gibson I. W., Blydt-Hansen T. D., Pochinco D., Birk P. E., Ho J., Karpinski M., Goldberg A., Storsley L., Rush D. N., Nickerson P. W., Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients WithDe NovoDonor-Specific Antibody : Post-dnDSA Clinical Histologic Progression, 10.1111/ajt.13347
  27. Kuypers D, Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients, 10.1016/j.clpt.2003.12.009
  28. Dirks N.L., Huth B., Yates C.R., Meibohm B., Pharmacokinetics of immunosuppressants: a perspective on ethnic differences, 10.5414/cpp42701
  29. Mancinelli L, The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups, 10.1067/mcp.2001.113183
  30. Andrews Louise M, De Winter Brenda CM, Van Gelder Teun, Hesselink Dennis A, Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus, 10.2217/pgs-2016-0136
  31. Laftavi M.R., Pankewycz O., Patel S., Nader N., Kohli R., Feng L., Said M., Dayton M., African American Renal Transplant Recipients (RTR) Require Higher Tacrolimus Doses to Achieve Target Levels Compared to White RTR: Does Clotrimazole Help?, 10.1016/j.transproceed.2013.09.010
  32. Narayanan Mohanram, Pankewycz Oleh, El-Ghoroury Mohamed, Shihab Fuad, Wiland Anne, McCague Kevin, Chan Laurence, Outcomes in African American Kidney Transplant Patients Receiving Tacrolimus and Mycophenolic Acid Immunosuppression : , 10.1097/tp.0b013e318277438f
  33. Beermann Kristi J., Ellis Matthew J., Sudan Debra L., Harris Matthew T., Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone, 10.1111/ctr.12376
  34. Vadivel Nidyanandh, Garg Ashwani, Holt David W., Chang Rene W. S., MacPhee Iain A. M., Tacrolimus Dose in Black Renal Transplant Recipients : , 10.1097/01.tp.0000259248.60448.8a
  35. Kim Jung Sue, Aviles Diego H., Silverstein Douglas M., LeBlanc Pamela L., Matti Vehaskari V., Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients, 10.1111/j.1399-3046.2005.00263.x
  36. Zhang Rubin, Donor-Specific Antibodies in Kidney Transplant Recipients, 10.2215/cjn.00700117
Bibliographic reference Rubik, Jacek ; Debray, Dominique ; Kelly, Deirdre ; Iserin, Franck ; Webb, Nicholas J A ; et. al. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.. In: Transplant international, Vol. 32, no. 11, p. 1182-1193 (2019)
Permanent URL http://hdl.handle.net/2078.1/219079